Alvotech

46.50 SEK

+9.93 %

Less than 1K followers

ALVO SDB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

+9.93 %

-8.82 %

-39.74 %

-57.73 %

-

-

-

-

-52.70 %

Alvotech is a biotechnology company that focuses on the development and manufacture of biosimilar medicines. The company's pipeline consists of biosimilar candidates aimed at treating autoimmune diseases, eye diseases, osteoporosis and cancer. The company offers its products to patients all over the world. Alvotech was founded in 2013 and has its headquarters in Reykjavík.

Market cap

15.1B SEK

Turnover

784.2K SEK

Revenue

5.43B

EBIT %

14.33 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All

Press releases

ShowingAll content types

Regulatory press release11/24/2025, 10:30 AM

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Regulatory press release11/20/2025, 9:00 AM

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Regulatory press release11/12/2025, 9:40 PM

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/10/2025, 9:00 AM

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)

Regulatory press release11/6/2025, 2:00 PM

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Regulatory press release11/4/2025, 9:01 PM

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Regulatory press release11/2/2025, 10:10 PM

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Regulatory press release10/22/2025, 9:00 AM

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Regulatory press release10/6/2025, 8:40 AM

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Regulatory press release9/22/2025, 10:15 AM

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®

Regulatory press release9/22/2025, 8:30 AM

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Regulatory press release9/19/2025, 11:45 AM

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Regulatory press release9/4/2025, 1:15 PM

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Regulatory press release8/21/2025, 8:30 AM

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Regulatory press release8/20/2025, 10:05 AM

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Regulatory press release8/13/2025, 8:15 PM

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Regulatory press release8/6/2025, 12:00 PM

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Regulatory press release7/10/2025, 8:40 AM

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Regulatory press release7/9/2025, 8:30 AM

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Regulatory press release7/3/2025, 11:02 PM

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.